Clinical Trials | May 14, 2026
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
High-resolution analytical platforms from Agilent Technologies will be made available through C-CAMP’s shared infrastructure model under expanded collaboration
The global JAK inhibitors market is projected to REACH $56.78 billion by 2030, reflecting strong demand for targeted immunology treatments
Industry veteran to lead Brinton’s expansion across India and key Asia Pacific markets
The medical-grade Angelas diode laser calibrated at a 1470 nm wavelength supports microsurgeries across multiple specialties
Lormalzi is the first and only once-monthly amyloid plaque-targeting therapy with clinical evidence
The two companies will establish a joint Center of Excellence (CoE) in Bengaluru
Subscribe To Our Newsletter & Stay Updated
